IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Corporate Highlights and Recent Developments Expanded Pipeline with INB-600 Gamma-Delta T Cell Engager Platform Demonstrated Additional Clinical Progress Across Gamma-Delta T Cell Therapy Pipeline NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the first quarter ended March 31, 2025 and recent corporate highlights. "IN8bio stands ...